Cambridge, UK, 2nd May 2019: Longer-term follow-up data published this week in Gut, by Professor Ken Smith’s team at the University of Cambridge, provides further validation of the whole blood-based biomarker test launched by PredictImmune in the UK and Ireland (https://gut.bmj.com/content/early/2019/04/27/gutjnl-2019-318343).
The paper, by Biasci and Lee et. al., describes the translation of the original CD8+ microarray-based biomarker to a whole blood-based qPCR test and includes longer term follow-up data from a number of inflammatory bowel disease (IBD) cohorts, including an independent validation cohort (n=123) and the “Cambridge cohort” (n=132).
Patients in the high-risk group required earlier and more frequent treatment escalations, as well as requiring the use of more potent medications to manage their disease.
The key take-home messages from the study are that the biomarker enables the classification of patients into those at either high- or low-risk of aggressive disease. Patients in the high-risk group required earlier and more frequent treatment escalations, as well as requiring the use of more potent medications to manage their disease. The paper demonstrates that the classifier is effective in both Crohn’s disease and ulcerative colitis populations, with follow- up extending to >4 years for the Cambridge cohort. The test is seen as the first step towards personalised medicine IBD, enabling clinicians to consider using more aggressive treatments earlier on for high-risk patients.
News of the publication was picked up rapidly by the scientific community with a follow up article appearing in Medpage this week (https://www.medpagetoday.com/gastroenterology/inflammatoryboweldisease/79514).